# LivaNova PLC > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/LivaNova PLC). ## Overview LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions. It designs, manufactures, and sells devices and related services through two main businesses: Cardiopulmonary and Neuromodulation, serving hospitals and specialist clinicians worldwide. ## Products & services • Cardiopulmonary bypass systems and accessories • Essenz Perfusion System and related monitoring technology • Oxygenators, cannulae, and perfusion tubing systems • Neuromodulation therapies for select neurological conditions • Hospital and provider training, service, and support - **Cardiopulmonary** (57%) — Products and services used in cardiopulmonary bypass and perfusion procedures, including HLMs, oxygenators, tubing, and cannulae. - **Neuromodulation** (43%) — Implantable and therapy-related products for select neurological conditions and associated clinical support. - **Other revenue** (1%) — Rental and site services income and legacy non-core revenue not allocated to the main segments. - Cardiopulmonary bypass systems and accessories - Essenz Perfusion System with embedded patient monitoring - Oxygenators, cannulae, and perfusion tubing systems - Autotransfusion systems and related services - Neuromodulation therapies for select neurological conditions - Training, education, and service support for providers ## Customers LivaNova sells primarily to hospitals, medical institutions, and healthcare providers that need specialized devices for cardiac surgery and neurological care. Its users also include perfusionists, neurologists, neurosurgeons, and other clinicians who influence product selection, training, and adoption. Purchasing decisions are driven by clinical performance, reliability, regulatory approval, and total cost of care. - **Hospitals and surgical centers** (primary) — Buy cardiopulmonary systems, oxygenators, cannulae, and related consumables for cardiac procedures; they value reliability, clinical outcomes, and vendor support. - **Specialist physicians and clinical teams** (primary) — Neurologists, neurosurgeons, and perfusionists influence adoption and use of therapies and systems based on efficacy, workflow, and training support. - **Healthcare purchasing organizations** (secondary) — Centralized procurement teams and preferred-vendor programs negotiate pricing and vendor access, affecting product mix and margins. - **Medical institutions and providers** (secondary) — Buy service, rental, and support offerings tied to installed equipment and ongoing clinical use. - Hospitals buying devices for cardiac surgery and perfusion procedures - Neurologists and neurosurgeons using therapies for select conditions - Perfusionists who specify and operate cardiopulmonary systems - Healthcare providers seeking reliable, regulated medical technologies - Purchasing groups and preferred-vendor programs focused on cost control ## Geography LivaNova reports three operating geographies: the United States, Europe, and Rest of World. In 2025, the U.S. represented 53% of net revenue, Europe 19%, and Rest of World 28%, showing a broad international footprint with meaningful exposure to reimbursement, regulatory, and currency differences across markets. - **United States** (53%) - **Europe** (19%) — Europe includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. - **Rest of World** (28%) — All other countries where LivaNova operates outside the U.S. and Europe. - United States is the largest market and a key driver of revenue - Europe is a major second market across several large healthcare systems - Rest of World adds diversification but increases regulatory complexity - Sales are made in more than 100 countries through direct and indirect channels - Global footprint exposes the company to FX, tariffs, and supply-chain risk ## Strategy LivaNova’s strategy centers on advancing its two core franchises, especially next-generation cardiopulmonary systems and differentiated neuromodulation therapies. The company is also focused on maintaining regulatory compliance, improving manufacturing quality, and expanding clinical relationships that support adoption in hospitals and specialist practices. - **Expand Essenz Perfusion System adoption** (medium-term) — The next-generation HLM is a key growth driver in Cardiopulmonary and supports recurring consumables demand. - **Protect and grow neuromodulation franchise** (medium-term) — Neuromodulation is a major revenue base and depends on clinical trust, reimbursement, and specialist adoption. - **Maintain regulatory and quality execution** (short-term) — Medical device commercialization depends on approvals, safety, and manufacturing quality to avoid disruptions and recalls. - **Preserve customer relationships and training** (short-term) — Clinical education and conference presence help drive adoption and defend share in specialized device markets. - Grow Essenz Perfusion System adoption in cardiopulmonary care - Strengthen consumables pull-through and installed-base economics - Support neuromodulation growth through clinical and commercial execution - Maintain high-quality manufacturing and timely regulatory approvals - Deepen relationships with clinicians, hospitals, and purchasing groups ## Risks LivaNova faces the typical risks of a global medical device company: regulatory scrutiny, pricing pressure, and competition from larger device makers and alternative therapies. Company-specific issues include supply-chain concentration, cybersecurity and data-protection exposure, and the potential for product safety or physician advisories to shift market share quickly. - **Global operating and trade risk** [high] — The company sells in many countries and is exposed to tariffs, sanctions, inflation, and local regulatory changes. - **Supply chain concentration and component shortages** [high] — Medical device manufacturing depends on qualified suppliers, and switching sources can be slow under regulatory constraints. - **Cybersecurity and data protection** [high] — The company handles sensitive patient and health data, so breaches can trigger regulatory, legal, and reputational damage. - **Pricing pressure and customer consolidation** [medium] — Hospitals and purchasing groups are reducing vendor counts and pushing for lower prices. - **Product safety and regulatory actions** [high] — Advisories, recalls, or competitor safety issues can rapidly alter demand and market share. - Global operations expose the company to tariffs, FX, and geopolitical shocks - Supply interruptions can limit production of regulated devices - Cybersecurity or data incidents could harm operations and reputation - Pricing pressure rises as hospitals centralize purchasing and use preferred vendors - Product advisories or safety alerts can quickly shift market share ## Accounting The most important accounting judgments are revenue recognition, goodwill and indefinite-lived intangible impairment testing, and provisions for contingencies. Reported results can also swing from environmental liabilities, debt extinguishment, foreign exchange, and tax-rate changes across jurisdictions. - **Revenue recognition and product mix** — Affects reported revenue timing and margin mix - **Goodwill and indefinite-lived intangible impairment** — Can create large non-cash impairment charges if assumptions weaken - **SNIA environmental liability** — Distorts operating and net income in the period recognized - **Income taxes across multiple jurisdictions** — Can cause large swings in effective tax rate - Revenue is affected by product mix, geography, and timing of device shipments - Goodwill and indefinite-lived intangibles require annual impairment testing - Environmental and legal contingencies can create large one-time charges - Foreign exchange and debt-related items can move pre-tax earnings materially - Multi-jurisdiction tax accounting depends on valuation allowances and local rates --- *Last updated: 2026-04-28T20:23:13.742991+00:00*